Predictive Analytics for Marketing Mix: The Future is now
Artificial Intelligence Drives Industry Response to Project Optimus
The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Bringing the Clinical Trials Industry Together
Micah Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and what attendees can expect at SCOPE.
FDA Approves Expanded Indication for HIV Therapy to Treat People with Suppressed Viral Loads, Pre-existing Resistance
Gilead’s Biktarvy is now the first and only INSTI-based single-tablet regimen that is FDA approved and DHHS guideline recommended for people who are virologically suppressed with M184V/I resistance.
Managing Digital Studies in the Current Landscape
Flo Mowlem, VP of Science at ObvioHealth discusses digital study design—touching on how to best manage data and medical devices.
FDA Reaches Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation
Biopharma company XYRA and FDA have concluded a series of Phase II meetings on managing key studies for potential atrial fibrillation therapy, budiodarone.
Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
Phase Ia, open-label, escalating dose study to evaluate the safety and immunogenicity of therapeutic vaccine, TherVacB.
2 Commerce Drive Cranbury, NJ 08512